127 results
Page 4 of 7
8-K
EX-99.1
1bgjsb
27 Feb 20
Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update
7:39am
424B5
s21utkyxpi83tm
22 Jan 20
Prospectus supplement for primary offering
5:31pm
424B5
79z2gy4e1jad6
21 Jan 20
Prospectus supplement for primary offering
5:21pm
8-K
oy29f4t8rg92wky3
14 Jan 20
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
6:17am
8-K
EX-99.1
51go4almw8wug
14 Jan 20
Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies
6:17am
8-K
EX-99.1
qt3ahm6b2 ow
13 Jan 20
Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications
7:09am
8-K
2ni y842y4cip4td5
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-99.1
otfp ac4sf
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-10.1
556mq7non8jlbr45
27 Aug 19
Entry into a Material Definitive Agreement
8:39am
8-K
EX-99.1
0fb 2q6tldiszv141t5
18 Jul 19
Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGE-A4 to Enhance Antitumor Responses
8:11am
8-K
EX-99.1
buhn x52f9v0coxjvuaj
15 May 19
Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products
8:11am
8-K
EX-99.1
vaek9ijep
6 May 19
Adaptimmune TRANSFORMING T CELL THERAPY Clinical and Business Update
8:11am